Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Revenue (2020 - 2025)

Historic Revenue for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $458.6 million.

  • Apellis Pharmaceuticals' Revenue rose 13298.18% to $458.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 4211.03%. This contributed to the annual value of $781.4 million for FY2024, which is 9702.09% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Revenue stood at $458.6 million for Q3 2025, which was up 13298.18% from $178.5 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Revenue registered a high of $458.6 million during Q3 2025, and its lowest value of $623000.0 during Q2 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Revenue value was $102.7 million (recorded in 2023), while the average stood at $118.0 million.
  • In the last 5 years, Apellis Pharmaceuticals' Revenue plummeted by 7588.4% in 2021 and then soared by 251990.37% in 2022.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Revenue stood at $60.3 million in 2021, then plummeted by 62.41% to $22.7 million in 2022, then soared by 545.89% to $146.4 million in 2023, then soared by 45.19% to $212.5 million in 2024, then skyrocketed by 115.77% to $458.6 million in 2025.
  • Its last three reported values are $458.6 million in Q3 2025, $178.5 million for Q2 2025, and $166.8 million during Q1 2025.